Brief: Synact Pharma Reports Top-Line Results From Phase 2A Study Of AP1189 In Early Rheumatoid Arthritis Patients Experiencing Severe Disease Activity

SynAct Pharma AB

30/11/2021 02:12

Nov 29 (Reuters) - SynAct Pharma AB  SYNACT.TE :
    * SYNACT PHARMA - TOP-LINE RESULTS FROM PHASE 2A STUDY OF
AP1189
IN EARLY RHEUMATOID ARTHRITIS PATIENTS EXPERIENCING SEVERE
DISEASE ACTIVITY
    * SYNACT PHARMA AB - AP1189 WAS WELL-TOLERATED AND PRESENTED
WITH
A FAVORABLE SAFETY PROFILE; NO SERIOUS ADVERSE EVENTS WERE
REPORTED IN STUDY
    * SYNACT PHARMA AB  SYNACT.TE  - SYNACT WILL SEEK SCIENTIFIC
ADVICE AND OPEN AN IND WITH FDA TO PREPARE FOR PHASE 2B 
    * SYNACT PHARMA AB  SYNACT.TE  - PHASE 2B WILL UTILIZE NEW
ONCE-DAILY TABLET FORMULATION AND WITH A LONGER TREATMENT
DURATION 

Source text for Eikon:  ID:nWkr6kTqXx 
Further company coverage:  SYNACT.TE 

 ((Reuters.Briefs@thomsonreuters.com;))